Browse articles from EyeWorld.org related to pain. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ 24-month pivotal data support efficacy of laser treatment for glaucoma
➤ Low-dose atropine drop meets primary, secondary endpoints in new data analysis
➤ Phase 2 topline data for modifier gene therapy for geographic atrophy
➤ Phase 2 data from study evaluating neuropathic corneal pain shows quality of life improvement
➤ New shelf-stable corneal endothelial cell therapy program begins
➤ ASCRS news and events
➤ New drop for temporary presbyopia relief approved
➤ First-in-human results for accommodating IOL
➤ Enrollment complete in Phase 2/3 trial for Stargardt therapy
➤ Type C meeting completed with FDA to advance urcosimod for neuropathic corneal pain
➤ Company news
➤ ASCRS news and events
➤ Study: low-dose pilocarpine reduces pupil diameter without significant ciliary muscle response
➤ First patient receives investigational surgical system for glaucoma
➤ Clinical program for RP gene therapy begins
➤ FDA approves IND for steroid-free, topical anti-inflammatory
➤ Compassionate use approved for investigational drug intended for neuropathic corneal pain
➤ Company news
➤ ASCRS news and events
➤ Priority review granted to possible LHON treatment
➤ Update on drug in development for neuropathic corneal pain
➤ FDA approves generic bimatoprost
➤ Phase 1/2a clinical results for first-in-human retinal pigment epithelial stem cell therapy
➤ Adult dosing complete in trial for X-linked retinoschisis therapy
➤ Company news
➤ ASCRS news and events
➤ Topline Phase 2 results for drug treating neuropathic corneal pain
➤ Phase 3 blepharitis treatment doesn’t meet primary endpoint
➤ Study: therapeutic potential of collagen mimetic peptides for myopia
➤ FDA accepts NDA resubmission for dry eye therapy
➤ Partnership news
➤ ASCRS news and events
➤ Long-term data on treatment for neuropathic corneal pain
➤ European agency issues positive opinion for low-dose atropine formulation
➤ Study: semaglutide use associated with increased risk of NAION
➤ Company news
➤ ASCRS news and events
➤ FDA accepts new drug application for pharmaceutical aiming to treat pediatric myopia
➤ FDA approves treatment for macular telangiectasia type 2
➤ Survey reveals perspectives of patients with glaucoma
➤ New wearable vision testing platform
➤ Seeking Fast Track Designation for investigational treatment of neuropathic corneal pain
➤ Fast Track Designation granted to gene therapy targeting X-linked retinoschisis
➤ ASCRS news and events
➤ Topline Phase 3 results for sublingual, opioid-free sedation
➤ Phase 1 results for non-surgical cell therapy for corneal edema
➤ First Phase 2 study evaluates wet AMD gene therapy in both eyes of patients
➤ Update on Phase 3 study evaluating treatment for progressive myopia
➤ FDA to review NDA for first-in-class dry eye treatment
➤ Enrollment complete for Phase 1/2 study evaluating novel IOP-lowering drug delivery platform
➤ ASCRS news and events
➤ Study: protein patterns in tears predict postop pain
➤ Tentative approval for generic glaucoma drug
➤ Nanodrug recovers optic nerve in glaucoma animal model
➤ Acquisition news
➤ ASCRS news and events
ASCRS EyeWorld Weekly: View the current issue
➤ Claes Dohlman, MD, PhD, dies at 101 years old
➤ Trial to evaluate neuropathic corneal pain drug
➤ FDA clears new OCT technology
➤ Study: supplements slow progression of late-stage dry AMD
➤ Young eye surgeon scholarship opportunity
➤ Acquisition news
➤ ASCRS news and events
